These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3824016)

  • 1. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.
    West WO
    South Med J; 1987 Mar; 80(3):323-7. PubMed ID: 3824016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
    Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of polycythemia vera with hydroxyurea.
    Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
    Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
    Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
    Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
    Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
    J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
    Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
    Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic transformation in polycythemia vera: analysis of risk factors.
    Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI
    Am J Hematol; 1990 May; 34(1):32-6. PubMed ID: 2327402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anesthesia for polycythemia vera.
    Sosis MB
    J Clin Anesth; 1990; 2(1):31-4. PubMed ID: 2178645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
    Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
    Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera in a 12-year-old girl: a case report.
    Turker M; Ozer EA; Oniz H; Atabay B; Yaprak I
    Pediatr Hematol Oncol; 2002 Jun; 19(4):263-6. PubMed ID: 12051593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polycythemia vera: current status of therapy].
    Lengfelder E; Hehlmann R
    Dtsch Med Wochenschr; 2000 Oct; 125(41):1243-7. PubMed ID: 11076265
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of polycythemia vera with hydroxyurea.
    Sharon R; Tatarsky I; Ben-Arieh Y
    Cancer; 1986 Feb; 57(4):718-20. PubMed ID: 3943010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.